Dare Bioscience (DARE) Income towards Parent Company (2016 - 2026)

Dare Bioscience (DARE) has 10 years of Income towards Parent Company data on file, last reported at -$1.6 million in Q4 2025.

• Quarterly Income towards Parent Company rose 69.4% year-over-year to -$1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$20.4 million (up 15.04% YoY) and the FY2025 annual result came in at -$127.3 million, up 8.41% from the prior year.
• Income towards Parent Company grew to -$1.6 million in Q4 2025, from -$5.8 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $304322.0 in Q2 2022 to a low of -$16.3 million in Q4 2022.
• A 5-year average of -$7.4 million and a median of -$7.4 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 103.28% — and 2023, when it slumped 3088.4%.
• Tracing DARE's Income towards Parent Company over 5 years: stood at -$9.7 million in 2021, then slumped by 68.7% to -$16.3 million in 2022, then jumped by 65.82% to -$5.6 million in 2023, then rose by 3.99% to -$5.3 million in 2024, then soared by 69.4% to -$1.6 million in 2025.
• The last three Income towards Parent Company figures came in at -$1.6 million (Q4 2025), -$5.8 million (Q3 2025), and -$5.9 million (Q2 2025), per Business Quant data.